Key result
A77 1726 attenuated pressure overload- or angiotensin II-induced cardiac hypertrophy and fibrosis in mice via inhibition of the FYN/AKT signaling pathway.
Why the study?
Does A77 1726 reduce cardiac hypertrophy and fibrosis in preclinical models?
Population
Mice with pressure overload or angiotensin II-induced cardiac hypertrophy in vivo, and cardiomyocytes in vitro
Design
Preclinical
Authors
Loading...
Hypothesis-generating in mice; human trials needed before considering A77 1726 for cardiac remodeling.
Does A77 1726 reduce cardiac hypertrophy and fibrosis in preclinical models?
A77 1726 (leflunomide) demonstrates cardioprotective effects by blocking and reversing cardiac hypertrophy and fibrosis through the FYN/AKT signaling pathway in preclinical models.
Ma et al. (2018) studied Cardiac hypertrophy and fibrosis. A77 1726 (leflunomide) was evaluated on Cardiac hypertrophy and fibrosis. A77 1726 attenuated pressure overload- or angiotensin II-induced cardiac hypertrophy and fibrosis in mice via inhibition of the FYN/AKT signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: